US2004219587A1PendingUtilityA1

Vaccine against lipopolysaccharide core

42
Priority: May 16, 1997Filed: Apr 6, 2004Published: Nov 4, 2004
Est. expiryMay 16, 2017(expired)· nominal 20-yr term from priority
Inventors:Elliott Bennett-GuerreroGeorge Robin BarclayIan Raymond PoxtonThomas James McintoshDavid Scott Snyder
Y02A50/30A61K 39/0275A61K 2039/55555
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Complete core LPS (lacking O-polysaccharide side chains) from Gram-negative bacteria are incorprated into a vaccine typically in liposomes. The complete core of E. coli K 12 is particularly useful. Upon administration to a mammal the vaccine stimulated synthesis of antibodies which are cross-protective against smooth and rough forms of LPS from at least two different Gram-negative bacterial strains having different core structures.

Claims

exact text as granted — not AI-modified
What is claimed:  
     
         1 . A method of quantitating lipopolysaccharide incorporated into liposomes by performing periodic acid/Schiff base staining.  
     
     
         2 . The method of  claim 1  in which the test is performed on a vaccine lot intended for clinical use.

Join the waitlist — get patent alerts

Track US2004219587A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.